Empagliflozin to Prevent Post-Operative Atrial Fibrillation
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical
trial with allocation sequence concealment and blinded endpoint adjudication. The goal of
present study is to investigate if periprocedural administration of 10 mg once daily
empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2I), can reduce the incidence
of post-operative atrial fibrillation and/or atrial flutter in patients with chronic coronary
syndrome scheduled for isolated CABG. This trial will be conducted in two referral teaching
cardiology hospitals in Tehran. 492 adult patients who are scheduled for elective isolated
coronary artery bypass graft (CABG) surgery will be randomly assigned to one of the groups of
intervention (empagliflozin 10 mg daily) or placebo starting 3 days before surgery until
discharge.